1.
Introduction rBCG30, the first vaccine against tuberculosis demonstrated more potent than BCG in preclinical studies, is the prototype of a class of recombinant vaccines against tuberculosis that utilize bacillus Calmette-Guérin or BCG as the host organism for expressing Mycobacterium tuberculosis major extracellular proteins. rBCG30 is a recombinant BCG Tice strain expressing large amounts of the M. tuberculosis 30 kDa major secretory protein, a mycolyl transferase also known as the α Antigen or Antigen 85B [1, 2] . The recombinant protein, designated r30, is expressed from the plasmid pMTB30 ( Fig.1 ) [2, 3] . Derived from the mycobacterium -E. coli shuttle vector pSMT3 (4] , pMTB30 contains a full-length copy of the M. tuberculosis 30 kDa major secretory protein gene and flanking 5' and 3' regions including its own promoter region (2] .
rBCG30 expresses 5-6 times more of the 30 kDa major secretory protein than the parental strain, which expresses and secretes a homologous endogenous 30 kDa protein that differs from the M. tuberculosis 30 kDa protein by two contiguous amino acids [1, 2] .
2.
Rationale for rBCG30 and other recombinant BCG vaccines expressing M.
tuberculosis major extracellular proteins
Life Style of M. tuberculosis
The design of a vaccine must take into account the life style of the pathogen against which the vaccine is targeted. In the case of M. tuberculosis, the central immunobiological feature of the organism is that it is an intracellular pathogen of human mononuclear phagocytes. After ingestion by conventional phagocytosis [5] , mediated primarily by complement receptors and mannose receptors [5, 6] , which recognize fragments of complement component C3 and lipoarabinomannan, respectively, on the bacterial surface [5] [6] [7] , the organism resides and multiplies within a membrane-bound phagosome. The phagosome, which is impermeable to small molecular weight substances in the cytoplasm [8] , interacts throughout its life cycle with early endosomes and to some extent late endosomes [9] . However, it arrests the maturation of its phagosome at an endosomal stage, and it does not proceed along the endolysosomal pathway to fuse with lysosomes [9] . The phagosomal membrane contains both MHC class I and II molecules but whether the MHC molecules on the phagosome are involved in presentation of M.
tuberculosis antigens is not known. The M. tuberculosis phagosome is only modestly acidified [9] [10] [11] .
Role of Cell-mediated Immunity
Against intracellular pathogens, cell mediated immunity plays a dominant role in host defense. In cell-mediated immunity, lymphocytes interact with macrophages in two major ways. First, they secrete lymphokines that activate mononuclear phagocytes such that they resist intracellular pathogens. One mechanism by which activated macrophages resist intracellular pathogens is by reducing their uptake, for example by downregulating complement receptor function [12] , as in the case of Mycobacterium leprae, thereby denying pathogens their preferred intracellular niche. Another way is to inhibit the multiplication of pathogens that are ingested by denying them access to essential nutrients, such as iron in the case of Legionella pneumophila [13, 14] , or by assaulting them with toxic oxygen molecules in the case of Toxoplasma gondii [15] . Second, 4 cytotoxic lymphocytes lyse infected macrophages, again denying the pathogens a host cell in which to multiply.
The Extracellular Protein Hypothesis
How are lymphocytes to recognize a host cell that is infected with an intracellular pathogen so that they can exert an antimicrobial effect against the host cell? How can a vaccine induce a population of lymphocytes in a naive host with the capability of recognizing infected macrophages at some later time when the host is infected?
Over fifteen years ago, we proposed a hypothesis to address these issues -the Extracellular Protein Hypothesis [16] [17] [18] [19] [20] [21] [22] . The Extracellular Protein Hypothesis has three major components. First, it holds that during natural infection, extracellular proteins of intracellular pathogens, i.e. proteins secreted or otherwise released by the organisms, play a key role in inducing cell-mediated immune responses and immunoprotection against this group of pathogens. Such proteins, by virtue of their release by live organisms into the intracellular compartment of the host cell, are available for proteolytic processing and subsequently presentation on the surface of the infected host cell as MHC-bound peptide fragments. These surface-exposed fragments serve as flags for the host immune system and allow the immune system to recognize live pathogens sequestered within a host cell and to exert an antimicrobial effect against them.
Second, the hypothesis holds that appropriate immunization of a naive host with extracellular proteins of intracellular pathogens can induce a population of lymphocytes capable of later recognizing and exerting an immune response against infected host cells.
These lymphocytes would recognize infected host cells by identifying MHC-bound 5 fragments of extracellular proteins displayed on the host cell surface consequent to the release of the proteins by the intracellular pathogen.
Finally, the hypothesis holds that among the extracellular proteins of intracellular pathogens, the major extracellular proteins, i.e. those released in greatest abundance, would figure prominently in inducing immunoprotection. We reasoned that such proteins, by virtue of their abundance in the phagosome, would provide the most plentiful display of MHC-peptide complexes on the surface of host cells, and therefore induce a particularly strong cell-mediated immune response.
Initial evidence in support of the Extracellular Protein Hypothesis derived from our studies of L. pneumophila, the agent of Legionnaires' Disease. Like M. tuberculosis, L. pneumophila is an intracellular respiratory pathogen transmitted by the airborne route and a facultative intracellular pathogen that resides throughout its intracellular life cycle within a phagosome [23, 24] . Like the M. tuberculosis phagosome, the L. pneumophila phagosome does not fuse with lysosomes and is not highly acidified [25, 26] . However, in contrast to the M. tuberculosis phagosome, the L. pneumophila phagosome does not interact with the endolysosomal pathway [9, 27] .
L. pneumophila secretes a single major protein, a 39 kDa metalloproteinase, designated Major Secretory Protein or MSP [16] . Interestingly, MSP is not a virulence determinant for L. pneumophila in human mononuclear phagocytes or in guinea pigs, an excellent small animal model of Legionnaires' disease [17] . Immunization of guinea pigs with MSP in adjuvant protects the animals from a lethal aerosol challenge with virulent L. pneumophila [16, 18] . In addition to MSP, L. pneumophila releases another major protein into its extracellular milieu, the major cytoplasmic membrane protein (MCMP), a 6 60 kDa heat shock protein [19] . This protein, which lacks a leader peptide, is probably released as a result of membrane blebbing. Immunization of guinea pigs with MCMP also protects the animals from lethal aerosol challenge with L. pneumophila [19] .
Immunization with MSP does not prevent infection with L. pneumophila. In guinea pigs immunized with MSP and challenged by aerosol with L. pneumophila, the bacterium multiplies several logs in the guinea pig lung during the first 24 hours after infection at a rate comparable to that of L. pneumophila in the lung of unimmunized animals [16] . However, by 24 hours, the infection is contained and the concentration of bacteria in the lung plateaus, generally at a level below that at which the animal exhibits signs of illness. In contrast, L. pneumophila continues to multiply in unimmunized animals until these animals succumb to the infection. The difference between immunized and control animals in the level to which L. pneumophila multiplies in the lungs is approximately 1.5 logs. This result indicates that for a vaccine to protect against disease and death, it must induce in the immunized animal a capacity to control infection but not necessarily to prevent it.
M. tuberculosis major extracellular proteins as immunoprotective antigens
M. tuberculosis secretes numerous proteins into its extracellular milieu of which 12 are particularly abundant [21] . The M. tuberculosis 30 kDa major secretory protein is the most abundant. It makes up almost one-quarter of the total extracellular protein released by M. tuberculosis into broth culture. This protein, as already noted, is a mycolyl transferase [28] . It is highly homologous to two other mycolyl transferases of mass 32 kDa, designated 32A (Antigen 85A) and 32B (Antigen 85C), that are also among the 12 7 major extracellular proteins [21, 29] . The M. tuberculosis 30 kDa protein is not only the major protein secreted into broth culture, but it is also among the major M. tuberculosis proteins of all types expressed in human macrophages infected with M. tuberculosis. [30] .
Initial studies in our laboratory examined the capacity of purified M. tuberculosis extracellular proteins in adjuvant to induce protective immunity against tuberculosis. For these studies, we utilized the outbred guinea pig model of pulmonary tuberculosis because of its high relevance to human tuberculosis. In contrast to the mouse and rat, the guinea pig is highly susceptible to M. tuberculosis, and it develops disease that closely resembles human tuberculosis clinically, immunologically, and pathologically [1, 2] . In these studies, we immunized the animals several times with protein in adjuvant and then challenged them by aerosol with the highly virulent Erdman strain of M. tuberculosis.
In further support of the Extracellular Protein Hypothesis, immunization of guinea pigs with a crude extract of M. tuberculosis extracellular proteins or with purified M.
tuberculosis extracellular proteins induced strong cell-mediated and protective immunity against aerosol challenge with M. tuberculosis [20, 21] . The M. tuberculosis 30 kDa major secretory protein as a single protein was a particularly potent vaccine [21] .
Combinations of the 30 kDa major secretory protein and other major extracellular proteins induced somewhat greater protection than the 30 kDa protein alone.
The use of strong adjuvants and powerful immunostimulators, such as IL-12, also enhanced protective immunity. However, even with the most potent combination of proteins and adjuvants, protection was modest in comparison with BCG, the currently 8 available vaccine. This result was unsatisfactory to us from a practical viewpoint since the ultimate goal of our studies was a vaccine more potent than BCG.
rBCG30
To obtain a more potent immune response to M. tuberculosis extracellular proteins, we turned to a live vector to express them. We reasoned that the most efficacious vector would be one that was avirulent on the one hand, but able to survive and replicate within the host for some period of time on the other. In addition, we considered that it may be important that the vector be capable of expressing and secreting 
Efficacy of rBCG30

Cell-mediated Immunity
Intradermal immunization of guinea pigs with rBCG30 induced strong cellmediated immune responses to r30 as evidenced by a vigorous cutaneous delayed-type hypersensitivity (DTH) response to r30 9 weeks after immunization (Fig. 3) . The cutaneous DTH response to r30 in guinea pigs immunized with rBCG30 Connaught or Tice was significantly greater than the negligible cutaneous DTH response of guinea pigs immunized with the parental strains. rBCG30 Tice, which produced the greatest amount of r30 --about 3-fold the amount produced by rBCG30 Connaught --consistently induced the strongest cutaneous DTH response and one significantly greater than that of rBCG30 Connaught (Fig. 3) [1, 2] .
Protective Immunity
To assess the capacity of rBCG30 to induce protective immunity, we immunized guinea pigs with either a parental BCG strain or a recombinant BCG strain [1] . The capacity of rBCG30 to protect against death after challenge was assessed in a subsequent study in which animals were sham-immunized, or immunized with either BCG or rBCG30, and 10 weeks later challenged with M. tuberculosis by aerosol (Fig. 5) [2]. As expected, sham-immunized animals died most rapidly. BCG-immunized animals survived significantly longer. Most importantly, rBCG30-immunized animals survived significantly longer than BCG-immunized animals. Thirty-five percent of the rBCG30-immunized animals survived to the point that uninfected control animals began to die.
4.2.
Safety of rBCG30
To assess the virulence of rBCG30, we immunized guinea pigs with rBCG30 Tice or BCG Tice and investigated the impact of immunization on the general health status of the animals [2] . No adverse health effects were noted for either group of animals. Both groups gained weight at the normal rate, including during the first 10 weeks after challenge when the animals harbored the highest numbers of bacteria in their organs.
We also assessed the clearance of the organisms by euthanizing animals at various intervals after immunization and assessing CFU in the regional lymph nodes, lung, and spleen. The parental BCG and rBCG30 exhibited an identical clearance profile (Fig. 6) [2]. CFU rose rapidly after immunization in all three sites, peaked at 3 weeks, and then declined such that by 10 weeks few organisms could be detected. Interestingly, low numbers of organisms (< 12) persisted in animal organs for at least 26 weeks after immunization [2] .
These studies demonstrated that rBCG30 and BCG are comparably avirulent. 
Stability of pMTB30 and Protein Expression in rBCG30
rBCG30 retains the plasmid pMTB30 and maintains high expression and secretion of r30 when subcultured in broth monthly in the absence of selective antibiotic pressure for at least one year. rBCG30 also stably maintains the pMTB30 plasmid in vivo in guinea pigs in the absence of antibiotic pressure for at least six weeks, as evidenced by the retention of hygromycin resistance in 100% of bacteria recovered from the lung, spleen, and regional lymph nodes six weeks after immunization.
5.
Other Recombinant BCG Expressing M. tuberculosis major extracellular proteins
Cole and colleagues reported the second tuberculosis vaccine superior to BCG [32] . Like rBCG30, this vaccine is a recombinant BCG expressing M. tuberculosis extracellular proteins. In this case, the vaccine expresses two proteins, ESAT-6 and CFP-10, whose homologs in BCG are absent because they are on a segment of the M. bovis genome that was deleted during the generation of BCG.
In our laboratory, we have generated and tested recombinant BCG expressing M.
tuberculosis major extracellular proteins other than the 30 kDa protein, including the 23.5
kDa protein (MPT64) [3] . This vaccine, rBCG23.5, was also more potent than BCG but 
6.
Manufacture of rBCG30
rBCG30 was manufactured by Good Manufacturing Practices at the Korean Institute of Tuberculosis using a protocol based on the procedure used in our laboratory to culture rBCG30. This process involves harvesting the organism at mid to late log phase. The manufactured lots were extensively tested to rule out contamination and to confirm that rBCG30 maintained its viability and capacity to express high amounts of the 30 kDa protein. Manufactured vaccine was also tested for endotoxin, residual moisture, and residual hygromycin to insure that it conformed to acceptable standards. The pMTB30 plasmid was recovered from the manufactured lot and its sequence was demonstrated to be identical to the plasmid isolated from the original seed lot.
7.
Human Clinical Trials. 
